← Find more feeds

astrazeneca.com

Press releases

Get the latest updates from Press releases directly as they happen.

Follow now 112 followers

Latest posts

Last updated over 2 years ago

Datopotamab deruxtecan showed encouraging and durable efficacy in patients with heavily pretreated HR-positive, HER2-low or negative metastatic breast cancer

over 2 years ago

Read full

Camizestrant significantly delayed disease progression in advanced ER-positive breast cancer, adding at least 3.5 months benefit versus Faslodex

over 2 years ago

Read full

Capivasertib plus Faslodex reduced the risk of disease progression or death by 40% versus Faslodex in advanced HR-positive breast cancer

over 2 years ago

Read full

Enhertu achieved statistically significant overall survival, reducing the risk of death by 36% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer in DESTINY-Breast03

over 2 years ago

Read full

AstraZeneca showcases strength of haematology portfolio and pipeline across multiple hard-to-treat conditions at ASH 2022

over 2 years ago

Read full

AstraZeneca announces sale of its West Chester, Ohio (US) manufacturing site

over 2 years ago

Read full

AstraZeneca to acquire Neogene Therapeutics, accelerating ambition in Oncology cell therapy

over 2 years ago

Read full

AstraZeneca aims to redefine breast cancer care with new data across the treatment spectrum at SABCS 2022

over 2 years ago

Read full

AstraZeneca ranked in top three in the Access to Medicine Index

over 2 years ago

Read full

Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive advanced gastric cancer

over 2 years ago

Read full

Imfinzi plus chemotherapy recommended for approval in the EU by CHMP as first immunotherapy regimen for advanced biliary tract cancer

over 2 years ago

Read full

Lynparza in combination with abiraterone recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic castration-resistant prostate cancer

over 2 years ago

Read full

Or log in

Everything you care about in one place

Press releases

Latest posts

Datopotamab deruxtecan showed encouraging and durable efficacy in patients with heavily pretreated HR-positive, HER2-low or negative metastatic breast cancer

Camizestrant significantly delayed disease progression in advanced ER-positive breast cancer, adding at least 3.5 months benefit versus Faslodex

Capivasertib plus Faslodex reduced the risk of disease progression or death by 40% versus Faslodex in advanced HR-positive breast cancer

Enhertu achieved statistically significant overall survival, reducing the risk of death by 36% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer in DESTINY-Breast03

AstraZeneca showcases strength of haematology portfolio and pipeline across multiple hard-to-treat conditions at ASH 2022

AstraZeneca announces sale of its West Chester, Ohio (US) manufacturing site

AstraZeneca to acquire Neogene Therapeutics, accelerating ambition in Oncology cell therapy

AstraZeneca aims to redefine breast cancer care with new data across the treatment spectrum at SABCS 2022

AstraZeneca ranked in top three in the Access to Medicine Index

Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive advanced gastric cancer

Imfinzi plus chemotherapy recommended for approval in the EU by CHMP as first immunotherapy regimen for advanced biliary tract cancer

Lynparza in combination with abiraterone recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic castration-resistant prostate cancer

Try Feeder for free